Investigational Drug Information for CP1-1189
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug CP1-1189?
CP1-1189 is an investigational drug.
There have been 4 clinical trials for CP1-1189. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are National Cancer Institute (NCI), H. Lee Moffitt Cancer Center and Research Institute, and Sheba Medical Center.
Summary for CP1-1189
|US Patent Applications||251|
|WIPO Patent Applications||111|
|Japanese Patent Applications||89|
|Clinical Trial Progress||Phase 2 (2009-07-01)|
Recent Clinical Trials for CP1-1189
|A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects||EA Pharma Co., Ltd.||Early Phase 1|
|Nilotinib Pre and Post Allogeneic Stem Cell Transplantation||Sheba Medical Center||Phase 2|
|Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)||University of Leipzig||Phase 1/Phase 2|
Clinical Trial Summary for CP1-1189
Top disease conditions for CP1-1189
Top clinical trial sponsors for CP1-1189
US Patents for CP1-1189
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|